These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19304557)

  • 1. Preclinical studies of [61Cu]ATSM as a PET radiopharmaceutical for fibrosarcoma imaging.
    Jalilian AR; Rostampour N; Rowshanfarzad P; Shafaii K; Kamali-Dehghan M; Akhlaghi M
    Acta Pharm; 2009 Mar; 59(1):45-55. PubMed ID: 19304557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive 64Cu-ATSM and PET/CT assessment of hypoxia in rat skeletal muscles and tendons during muscle contractions.
    Skovgaard D; Kjaer M; Madsen J; Kjaer A
    J Nucl Med; 2009 Jun; 50(6):950-8. PubMed ID: 19443591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
    Yuan H; Schroeder T; Bowsher JE; Hedlund LW; Wong T; Dewhirst MW
    J Nucl Med; 2006 Jun; 47(6):989-98. PubMed ID: 16741309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
    Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
    J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basic characterization of 64Cu-ATSM as a radiotherapy agent.
    Obata A; Kasamatsu S; Lewis JS; Furukawa T; Takamatsu S; Toyohara J; Asai T; Welch MJ; Adams SG; Saji H; Yonekura Y; Fujibayashi Y
    Nucl Med Biol; 2005 Jan; 32(1):21-8. PubMed ID: 15691658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human biodistribution and dosimetry of the PET perfusion agent copper-62-PTSM.
    Wallhaus TR; Lacy J; Whang J; Green MA; Nickles RJ; Stone CK
    J Nucl Med; 1998 Nov; 39(11):1958-64. PubMed ID: 9829589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).
    Dehdashti F; Grigsby PW; Lewis JS; Laforest R; Siegel BA; Welch MJ
    J Nucl Med; 2008 Feb; 49(2):201-5. PubMed ID: 18199612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study.
    Minagawa Y; Shizukuishi K; Koike I; Horiuchi C; Watanuki K; Hata M; Omura M; Odagiri K; Tohnai I; Inoue T; Tateishi U
    Ann Nucl Med; 2011 Jun; 25(5):339-45. PubMed ID: 21327756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
    O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production and tumour uptake of [64Cu]Pyruvaldehyde-bis (N4-methylthiosemicarbazone) for PET and/or therapeutic purposes.
    Jalilian AR; Rowshanfarzad P; Kamrani YY; Shafaii K; Mirzaii M
    Nucl Med Rev Cent East Eur; 2007; 10(1):6-11. PubMed ID: 17694494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High purity production and potential applications of copper-60 and copper-61.
    McCarthy DW; Bass LA; Cutler PD; Shefer RE; Klinkowstein RE; Herrero P; Lewis JS; Cutler CS; Anderson CJ; Welch MJ
    Nucl Med Biol; 1999 May; 26(4):351-8. PubMed ID: 10382836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue perfusion of copper-62-PTSM: relevance of studies in animal models as predictors of clinical radiopharmaceutical performance.
    Fritzberg AR
    J Nucl Med; 1995 Aug; 36(8):1456-7. PubMed ID: 7629594
    [No Abstract]   [Full Text] [Related]  

  • 13. Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma.
    Tateishi K; Tateishi U; Sato M; Yamanaka S; Kanno H; Murata H; Inoue T; Kawahara N
    AJNR Am J Neuroradiol; 2013 Jan; 34(1):92-9. PubMed ID: 22700754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines.
    Vāvere AL; Lewis JS
    Nucl Med Biol; 2008 Apr; 35(3):273-9. PubMed ID: 18355682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
    Dence CS; Ponde DE; Welch MJ; Lewis JS
    Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.
    Aft RL; Lewis JS; Zhang F; Kim J; Welch MJ
    Cancer Res; 2003 Sep; 63(17):5496-504. PubMed ID: 14500386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer.
    Takahashi N; Fujibayashi Y; Yonekura Y; Welch MJ; Waki A; Tsuchida T; Sadato N; Sugimoto K; Itoh H
    Ann Nucl Med; 2000 Oct; 14(5):323-8. PubMed ID: 11108159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET.
    Laforest R; Dehdashti F; Lewis JS; Schwarz SW
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):764-70. PubMed ID: 15785955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.
    Dehdashti F; Mintun MA; Lewis JS; Bradley J; Govindan R; Laforest R; Welch MJ; Siegel BA
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):844-50. PubMed ID: 12692685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comments on the feasibility of 61Cu production by proton irradiation of (nat)Zn on a medical cyclotron.
    Szelecsényi F; Steyn GF; Kovács Z; van der Walt TN; Suzuki K
    Appl Radiat Isot; 2006 Jul; 64(7):789-91. PubMed ID: 16545571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.